Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
October 07 2019 - 7:00AM
Surface Oncology (Nasdaq: SURF), a clinical-stage
immuno-oncology company developing next-generation immunotherapies
that target the tumor microenvironment, today announced that the
company will host its inaugural Analyst and Investor Day on Monday,
November 18, 2019, at the Nasdaq Marketsite, 4 Times Square, 10th
Floor, New York, NY.
Formal presentations will take place
from 8:00 a.m-11:00 a.m. ET, followed by questions and answers from
the full panel of presenters. Presentations will cover a variety of
topics, including:
- Corporate overview and strategic update: Jeff Goater, chief
executive officer of Surface Oncology
- Keynote presentation by Dr. E. John Wherry: Emerging trends in
T cell exhaustion and immunotherapy of cancer
- Overview and update of SRF617, a novel, potential best-in-class
anti-CD39 antibody: Robert Ross, M.D., chief medical officer of
Surface Oncology ° CD39 is an enzyme critical to both
the production of immunosuppressive adenosine and the breakdown of
pro-inflammatory adenosine triphosphate (ATP).
- Overview and update of SRF388, a first-in-class antibody
targeting IL-27: Vito Palombella, Ph.D., chief scientific officer
of Surface Oncology ° IL-27 is an
immunosuppressive cytokine involved in resolving T cell mediated
inflammation. Elevated levels of IL-27 and IL-27 induced gene
expression signatures have been identified in certain types of
cancer.
- Introduction to Surface’s first natural killer (NK) cell
targeting program, SRF813, a highly differentiated approach to
targeting CD112R: Pamela Holland, Ph.D., vice president of biology
at Surface Oncology ° CD112R is a recently
identified immune checkpoint protein that contributes to both
T cell and NK cell suppression through its role as an
inhibitory receptor. Blockade of CD112R promotes antitumor
responses through innate and adaptive arms of the immune
system.
A live webcast of the Analyst and Investor Day will be available
on the Surface Oncology website at
https://investors.surfaceoncology.com/news-events/events.
About Dr. John Wherry:
E. John Wherry, Ph.D., is the Richard and
Barbara Schiffrin President’s Distinguished Professor, chair of the
Department of Systems Pharmacology and Translational Therapeutics,
and director of the Penn Institute for Immunology at the Perelman
School of Medicine at the University of Pennsylvania. He is the
co-director of the Parker Institute for Cancer Immunotherapy at
Penn, as well as a member of the Scientific Advisory Board of
Surface Oncology. His research has focused on T cell exhaustion in
chronic viral infections and cancer. His work has defined the
developmental biology and molecular regulation of T cell
exhaustion, role of checkpoints including PD-1, LAG-3 and others
and significantly informed the development of immunotherapies for
human cancer.
About Surface Oncology: Surface
Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment with lead programs targeting CD73, CD39, IL-27 and
CD47. Surface’s novel cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. The
Company has a pipeline of seven novel immunotherapies and a
strategic collaboration with Novartis focused on NZV930
(CD73) and potentially one additional undisclosed program. For more
information, please visit www.surfaceoncology.com.
Contacts: Seth Lewis slewis@surfaceoncology.com
617-665-5031
Ten Bridge Communications Krystle Gibbs
krystle@tenbridgecommunications.com 508-479-6358
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Sep 2023 to Sep 2024